Shots:
- Daiichi Sankyo and Merck reported efficacy results for raludotatug deruxtecan (R-DXd) in patients with recurrent Pt.-resistant ovarian, primary peritoneal, or fallopian tube cancer from the P-II (dose-optimization) part of the REJOICE-Ovarian01 P-II/III study
- Across all doses (4.8 mg/kg, 5.6 mg/kg, and 6.4 mg/kg), ORR was 50.5% (n=107) as assessed by BICR, with 3 complete and 51 partial responses and a DCR of 77.6%; the safety profile was consistent with earlier findings
- Based on study data, the 5.6 mg/kg dose was selected for the P-III study that will enroll ~710 pts, which will compare R-DXd with the investigator’s choice of CT; the therapy recently received BTD (Sep 2025) from the US FDA
Ref: Merck | Image: Daiichi Sankyo and Merck | Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
